{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:00:58Z","timestamp":1790665258199,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.soc.2017.01.004","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T20:15:37Z","timestamp":1494533737000},"page":"467-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Radiotherapy for Anal Cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Serguei A.","family":"Castaneda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay B.","family":"Romak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2017.01.004_bib1","unstructured":"National Institutes of Health, National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: anal cancer. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/anus.html\/. Accessed September 30, 2016."},{"key":"10.1016\/j.soc.2017.01.004_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: A review and synthetic analysis","volume":"13","author":"De Martel","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soc.2017.01.004_bib3","unstructured":"Centers for Disease Control and Prevention. HPV-associated anal cancer rates by race and ethnicity. Available at: http:\/\/www.cdc.gov\/cancer\/hpv\/statistics\/anal.htm\/. Accessed September 30, 2016."},{"issue":"10","key":"10.1016\/j.soc.2017.01.004_bib4","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L","article-title":"Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal","volume":"51","author":"Nigro","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2017.01.004_bib5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer-phase III EORTC","volume":"15","author":"Bartelink","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2017.01.004_bib6","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin","volume":"348","author":"Northover","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2017.01.004_bib7","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.soc.2017.01.004_bib8","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"issue":"35","key":"10.1016\/j.soc.2017.01.004_bib9","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2017.01.004_bib10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soc.2017.01.004_bib11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.rpor.2015.05.010","article-title":"Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: review of the literature","volume":"20","author":"Gonzalez Ferreira","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"issue":"4","key":"10.1016\/j.soc.2017.01.004_bib12","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ijrobp.2004.09.030","article-title":"Radical radiotherapy for cervix cancer: the effect of waiting time on outcome","volume":"61","author":"Choan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2017.01.004_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijrobp.2007.12.027","article-title":"Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08","volume":"72","author":"Konski","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.soc.2017.01.004_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijrobp.2005.05.052","article-title":"Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal\/femoral nodes","volume":"63","author":"Chen","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.soc.2017.01.004_bib15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijrobp.2005.02.030","article-title":"Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome","volume":"63","author":"Milano","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.soc.2017.01.004_bib16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","article-title":"Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy","volume":"70","author":"Mell","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.soc.2017.01.004_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.soc.2017.01.004_bib18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.clon.2014.08.001","article-title":"Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation","volume":"26","author":"Muirhead","year":"2014","journal-title":"Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2017.01.004_bib19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2017.01.004_bib20","unstructured":"Myerson RJ, Garofalo MC, El Naqa I, et\u00a0al. Elective clinical target volumes in anorectal cancer: an RTOG consensus panel contouring atlas. Available at: https:\/\/www.rtog.org\/LinkClick.aspx?fileticket=DgflROvKQ6w=&tabid=231."},{"issue":"2S","key":"10.1016\/j.soc.2017.01.004_bib21","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.ijrobp.2016.06.260","article-title":"Stepwise multicenter introduction of intensity modulated radiation therapy for anal cancer in the United Kingdom: from consensus guidance to large-scale prospective audit, prior to future clinical trials","volume":"96","author":"Gilbert","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.soc.2017.01.004_bib22","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2017.01.004_bib23","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.ijrobp.2012.12.008","article-title":"Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study","volume":"85","author":"Deenen","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.soc.2017.01.004_bib24","unstructured":"ISRCTN registry. PLATO - Personalising anal cancer radiotherapy dose. ISRCTN88455282. Available at: http:\/\/www.isrctn.com\/. Accessed September 27, 2016."},{"key":"10.1016\/j.soc.2017.01.004_bib25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2017.01.004_bib26","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1200\/jco.2012.30.15_suppl.4030","volume":"30","author":"Garg","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.soc.2017.01.004_bib27","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/cncr.28045","article-title":"Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma","volume":"119","author":"Olivatto","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.soc.2017.01.004_bib28","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2017.01.004_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3503","article-title":"NCI9673: a multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA)","volume":"34","author":"Morris","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.soc.2017.01.004_bib30","article-title":"Two-year outcomes of RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"29","author":"Kachnic","year":"2011","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320717300042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320717300042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:01:03Z","timestamp":1760961663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320717300042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1055320717300042"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2017.01.004","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy for Anal Cancer","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2017.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}